Teacher Retirement System of Texas Purchases 184,915 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teacher Retirement System of Texas boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 38.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 662,797 shares of the company’s stock after purchasing an additional 184,915 shares during the period. Teacher Retirement System of Texas’ holdings in Teva Pharmaceutical Industries were worth $14,608,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC grew its stake in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after acquiring an additional 496 shares in the last quarter. Sanctuary Advisors LLC grew its stake in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after acquiring an additional 699 shares in the last quarter. Metis Global Partners LLC grew its stake in Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock worth $302,000 after acquiring an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after acquiring an additional 872 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TEVA shares. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Down 0.4 %

NYSE TEVA opened at $16.18 on Friday. The stock has a market cap of $18.34 billion, a P/E ratio of -11.16, a P/E/G ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a fifty day simple moving average of $17.79 and a two-hundred day simple moving average of $18.21. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.